Alentis to Present Data at ESMO Immuno-Oncology Congress showing Claudin-1 Targeting Antibody ALE.C04 Restored T-cell Infiltration and Checkpoint Inhibitor Efficacy in Pre-clinical Mouse Tumor Model

Alentis’ lead oncology asset, ALE.C04, is the first potential treatment to target Claudin-1 to make solid tumors vulnerable to treatmentBasel, Switzerland, December 1, 2022 – Alentis Therapeutics, the Claudin-1 company, today announced that Alberto Toso, Head of Oncology, will present a poster at the ESMO Immuno-Oncology Congress in Geneva, Switzerland (and virtually), from 7-9 December 2022. The poster, CLAUDIN-1 Targeting Antibodies in Solid Tumors: from ALE.C04 to CLAUDIN-1 Oncology Platform, presents evidence that non-junctional Claudin-1 is overexpressed in different solid tumors, drives T-cell exclusion and resistance to checkpoint inhibitors (CPI). Importantly, the use of non-junctional Claudin-1-targeting monoclonal antibody ALE.C04…

Continue ReadingAlentis to Present Data at ESMO Immuno-Oncology Congress showing Claudin-1 Targeting Antibody ALE.C04 Restored T-cell Infiltration and Checkpoint Inhibitor Efficacy in Pre-clinical Mouse Tumor Model

Alentis Therapeutics Announces Presentations at AASLD The Liver Meeting® 2022

Basel, Switzerland, November 4, 2022 – Alentis Therapeutics, a clinical stage biotechnology company focused on the development of breakthrough treatments for fibrotic diseases and cancer, today announced that there will be two presentations about the treatment of biliary disease and cancer using Claudin-1 monoclonal antibodies at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2022, taking place from November 4th to 8th in Washington DC, USA. Presentation: TREATMENT OF CHOLANGIOCARCINOMA WITH A HUMANIZED ANTI-CLAUDIN-1 MONOCLONAL ANTIBODY Presenter: Marion Muller, MS, Inserm, U1110 and University of Strasbourg, France Session: Parallel 22: Experimental and Translational Hepatobiliary…

Continue ReadingAlentis Therapeutics Announces Presentations at AASLD The Liver Meeting® 2022

Article published in The Journal of Hepatology highlights potential of Claudin-1 as a novel target for the treatment of hepatocellular carcinoma

Breakthrough results provide robust pre-clinical proof-of-concept for Claudin-1 monoclonal antibodies as potential first in-class compounds for HCCPotential shown to break the plateau of limited treatment response in advanced HCCThese results pave the way for the clinical development of Claudin-1 specific antibodies for treatment of patients with HCCBasel, Switzerland – 2 November 2022 Alentis Therapeutics (“Alentis” or “the Company”), the biotechnology company developing breakthrough treatments for organ fibrosis and fibrotic-associated cancers, today announces that Scientific Founder Professor Thomas Baumert’s team has published an article on the role of Claudin-1 (CLDN1) in the treatment of hepatocellular carcinoma (HCC) The Journal of…

Continue ReadingArticle published in The Journal of Hepatology highlights potential of Claudin-1 as a novel target for the treatment of hepatocellular carcinoma

Swiss Innovation Agency to Co-fund Research Collaboration to Accelerate Discovery of Biomarkers for Fibrosis

Alentis will collaborate with the FHNW School of Life Sciences to identify translational biomarkers of Claudin-1 for use in future Alentis trialsBasel, Switzerland – 27 September 2022 Alentis Therapeutics (“Alentis” or “the Company”), the biotechnology company developing breakthrough treatments for organ fibrosis and fibrotic-associated cancers, today announced the Swiss Innovation Agency, Innosuisse, will co-fund a research collaboration with the FHNW School of Life Sciences to accelerate the discovery of Claudin-1-associated biomarkers for fibrosis.Claudin-1 (CLDN1) is a novel, previously unexploited target with a unique mechanism of action that plays a key role in the pathology of organ fibrosis and fibrotic…

Continue ReadingSwiss Innovation Agency to Co-fund Research Collaboration to Accelerate Discovery of Biomarkers for Fibrosis

Alentis Therapeutics starts First-in-Human Clinical Trial for the Treatment of Liver and Kidney Fibrosis

Alentis Therapeutics Starts First-in-Human Clinical Trial for the Treatment ofLiver and Kidney Fibrosis FDA greenlights Alentis Phase 1 protocol study designAlentis to begin transition from pre-clinical to clinical Basel, Switzerland., 04 January 2022 -- Alentis Therapeutics, AG today announced it has dosed the first cohort of healthy participants in a first-in-human Phase 1 clinical trial of ALE.F02, a monoclonal antibody highly selective for Claudin-1, currently being developed for the treatment of advanced unmet liver and kidney fibrosis. Alentis is a clinical stage biopharma focused on discovering and developing novel therapies for the treatment of unmet fibrotic diseases. "ALE.F02 has…

Continue ReadingAlentis Therapeutics starts First-in-Human Clinical Trial for the Treatment of Liver and Kidney Fibrosis

Alentis Therapeutics announces Board appointments

Alentis Therapeutics Announces Appointments of Luca Santarelli to the Board of Directors and Rafaèle Tordjman as Chairperson Basel, Switzerland – 9 November 2021 Alentis Therapeutics, the Swiss biotech developing breakthrough treatments for fibrotic diseases, announced today the appointments of Luca Santarelli, M.D. as independent Non-Executive Director, and Rafaèle Tordjman, M.D. PhD as Chairperson of its Board of Directors, with immediate effect.Dr. Roberto Iacone, Chief Executive Officer of Alentis Therapeutics, commented: “Luca is a highly experienced entrepreneur in the life sciences sector and his successful track record in driving drug programs from discovery to commercialization will be invaluable as we…

Continue ReadingAlentis Therapeutics announces Board appointments

New Head of Oncology for Alentis

BASEL, Switzerland -- (01 November 2021) Alentis Therapeutics, the Swiss biotech developing breakthrough treatments for fibrotic diseases, announced today that Alberto Toso has joined the team as Head of Oncology, effective this month. “I‘m truly excited to continue my fight against cancer at Alentis. I believe the team has the potential to deliver transformative drugs that cancer patients need so urgently.” Welcoming Mr. Toso to the company, Dr. Roberto Iacone, CEO of Alentis said, “Alberto is a tremendous addition to our team with innovative leadership, very deep expertise in Oncology and unwavering commitment to fight cancer.” Alberto brings more…

Continue ReadingNew Head of Oncology for Alentis

New Head of Fibrosis for Alentis

BASEL, Switzerland -- (19 October 2021) Alentis Therapeutics, the Swiss biotech developing breakthrough treatments for fibrotic diseases, announced today that Geoffrey Teixeira has joined the team as Head of Fibrosis. Geoffrey brings more than 9 years of industrial drug development experience in inflammatory and fibrotic diseases. He was most recently Translational Research Lead of Fibrosis at Galapagos, Mechelen, Belgium. At Galapagos he was responsible for leading translational activities for the company’s fibrosis pipeline, and for reverse translation activities and platform development, combining multi-omics and machine learning approaches for the identification of new targets and biomarkers. Prior to Galapagos, Geoffrey…

Continue ReadingNew Head of Fibrosis for Alentis

Alentis Therapeutics Raises USD 67 Million in Series B Financing

About: Alentis Therapeutics, the Swiss biotech developing breakthrough treatments for fibrotic diseases, today announced that it has raised USD67 (CHF60) million in a Series B financing round. The funding will be used primarily for proof-of-concept clinical trials of Alentis’ first-in-class, Claudin-1 targeting, anti-fibrotic molecules in advanced liver and kidney fibrosis, and support ongoing drug discovery programs targeting other fibrotic diseases and hepatobiliary cancers. Morningside Venture Investments led the financing, joined by Jeito Capital and Series A investors BioMed Partners, BB Pureos Bioventures, Bpifrance through its InnoBio 2 fund, High-Tech Gründerfonds and Schroders Capital. Alentis welcomes Jason Dinges of Morningside…

Continue ReadingAlentis Therapeutics Raises USD 67 Million in Series B Financing

End of content

No more pages to load